Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
The presence of migraine and increasing headache pain intensity are associated with higher rates of anxiety, depression, inflammation, and sleep conditions, among other disorders.
Emotions, cognitions, and behaviors are significantly associated with pain severity and pain-related interference in IBD, including pain-specific cognitions and behaviors.
Researchers find that racial differences in pain may be rooted in life experience, rather than intrinsic biology.
Biohaven announced that rimegepant is now available for the acute treatment of migraine with or without aura in adults.
Compared with people without migraine, people with migraine and migraine with medication overuse headache often have deficits in metacognition.
Phase 2 clinical trials investigating lasmiditan reported higher incidence and severity of TEAEs, compared with the phase 3 studies.
Treatment with humanized monoclonal antibody galcanezumab for up to 1 year was safe and tolerable for episodic and chronic migraine prophylaxis.
The Patient-Reported Outcomes Measurement Information System (PROMIS) assessing physical function and pain interference with computer adaptive tests offers a streamlined, effective approach for measuring self-reported outcomes in patients with chronic low back pain.
Severe vitamin D deficiency was linked to lumbar degenerative disease and low back pain in postmenopausal women.